ITP Education Kit
Learn more about ITP and WinRho® when you order the ITP Educational Resource Kit
ITP Juego Educativo
Aprenda más acercade ITPy WinRho® cuando usted ordena el ITP Juego Educativo de Recurso
Tolerability1
In clinical trials of subjects with childhood acute ITP, adults and children with chronic
ITP, and adults and children with ITP secondary to HIV, only 7% of infusions were
associated with at least one adverse event related to WinRho® SDF.
| WinRho® SDF Tolerability* | |
Most Common Adverse Events |
Frequency † |
Headache |
2% |
Chills |
<2% |
Fever |
1% |
† n=848 infusions
*Studies were performed using WinRho®/WinRho® SD
WinRho® SDF Liquid is Bioequivalent to WinRho® SDF Lyophilized1
In two comparative pharmacokinetic studies (n=101), the formulations were bioequivalent following IV administration based on area under the curve to 84 days and had comparable pharmacokinetics following IM administration. Both formulations also had similar elimination half-lives. WinRho® SDF must be administered via the intravenous route for the treatment of ITP.
Please see the Important Risk Information for WinRho® SDF for more detailed risk information and the Prescribing Information for full prescribing details.
- WinRho® SDF [Rho(D) Immune Globulin Intravenous (Human)] package insert, Cangene Corporation, Winnipeg, Canada. Baxter Healthcare Corporation, Westlake Village, CA, USA, April 2006.
